Search results for "colorectal neoplasm"

showing 10 items of 499 documents

A widely used sampling device in colorectal cancer screening programmes allows for large-scale microbiome studies.

2018

We read with interest the article by Passamonti et al ,1 reporting the performance of two different faecal immunochemical tests (FITs) highlighting the importance of standardisation and validation of screening methodologies. Conventionally, laboratory-based FIT is the preferred approach in testing for occult blood in faeces, which includes colorectal cancer screening programmes.2–4 The potential of preserving stable faecal samples in a widely used FIT buffer for microbiome research would enable prospective microbiome studies in generally healthy subjects undergoing colorectal cancer screening. For this purpose, we evaluated faecal sample stability in the commonly used OC-Sensor (Eiken Chemi…

0301 basic medicineVeterinary medicine2312BiologySampling device03 medical and health sciencesHemoglobins0302 clinical medicineHumansMass Screening1506Microbiomecolonic microfloraEarly Detection of CancerMicrobiotaGastroenterologyHealthy subjectsIllumina miseqIon semiconductor sequencingPostScriptSample stabilityGastrointestinal Microbiome030104 developmental biologyColorectal cancer screeningMetagenomicsOccult Bloodepidemiology030211 gastroenterology & hepatologyGuaiacColorectal NeoplasmsGut
researchProduct

Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.

2020

Objective. To determine the factors related with diverting ileostomy performance after colorectal resection and anastomosis, in advanced ovarian cancer cytoreductive surgery. Methods. We have previously demonstrated the risk factors associated with anastomotic leak after colorectal anastomosis: Advanced age at surgery, low serum albumin level, additional bowel resections, manual anastomosis and distance of the anastomosis from the anal verge. However, use of diverting ileostomy is strongly variable and depends on individual surgeon preferences and training. Eight hospitals participated in this retrospective study. Data of 695 patients operated for ovarian cancer with primary colorectal anas…

0301 basic medicinemedicine.medical_specialtyBevacizumabAnastomotic LeakGynecologic oncologyAnastomosisStomaCohort Studies03 medical and health sciences0302 clinical medicineDiverting ileostomyOvarian cancerAnastomotic leakMedicineHumansPractice Patterns Physicians'AgedNeoplasm StagingRetrospective StudiesOvarian Neoplasmsbusiness.industryIleostomyAnastomosis SurgicalObstetrics and GynecologyRetrospective cohort studyPerioperativeCytoreduction Surgical Proceduresmedicine.diseaseNeoadjuvant TherapySurgeryBevacizumab030104 developmental biologyRisk factorsOncology030220 oncology & carcinogenesisCohortFemaleRisk factorbusinessOvarian cancerColorectal Neoplasmsmedicine.drugGynecologic oncology
researchProduct

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO…

2017

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account t…

0301 basic medicinemedicine.medical_specialtyChinaColorectal cancerDrug availabilityEthnic groupTaiwanConsensuSystemic therapyScientific evidence03 medical and health sciences0302 clinical medicineAsian PeopleRepublic of KoreaAsian countrymedicineHumansNeoplasm MetastasisReimbursementClinical OncologyClinical practice guidelinePan-Asianbusiness.industryMalaysiaHematologymedicine.diseaseColorectal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicinebusinessColorectal NeoplasmsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter …

2020

ABSTRACT Resection of colorectal liver metastases (CRLM) is a potential curative treatment for patients with metastatic colorectal cancer (mCRC) with liver-limited disease (LLD). Although long-term survival improved considerably within the last decades, high recurrence rates of 50-75% after resection remain a major challenge.Tecemotide (L-BLP25) is an antigen-specific cancer vaccine inducing immunity against mucin-1 (MUC1). The LICC trial aimed to improve survival in patients with mCRC after R0/R1 resection of CRLM. LICC was a binational, randomized, double-blind, placebo-controlled, multicenter phase 2 study including patients with R0/R1 resected CRLM without evidence of metastatic disease…

0301 basic medicinemedicine.medical_specialtyLung Neoplasmsmucin-1 (muc1)Colorectal cancermedicine.medical_treatmentImmunologyMedizinPlaceboCancer VaccinesGastroenterologyResectionDouble blind03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungGermanyInternal medicinemedicineHumansImmunology and AllergyRC254-282Original ResearchMembrane Glycoproteinsresection of colorectal liver metastasesbusiness.industryLiver NeoplasmsVaccinationNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal neoplasmsRC581-607medicine.diseasedigestive system diseasesVaccination030104 developmental biologyOncologyCurative treatment030220 oncology & carcinogenesistecemotide (l-blp25)TecemotideNeoplasm Recurrence LocalImmunologic diseases. AllergybusinessAdjuvantResearch Articleliver-limited diseaseOncoImmunology
researchProduct

Complication of endoscopic tattooing: a case report of covered perforation

2016

Aim Laparoscopy is considered a good approach in treatment of colorectal neoplastic diseases; the endoscopic tattooing is then recommended (Evidence Level III and grade of recommendation A) to mark a lesion or a polypectomy site for intraoperative identification. We describe the case of perforation after tattoing treated conservatively. Case report 63 years old woman, underwent colonoscopy for lipoma tattooing with India ink SPOT® solution kit and saline test. Immediately after the procedure the patient has been referred the appearance of colic epi-mesogastric pain and fever; Computed Tomography (CT) without MDC identified an irregular thickening of transverse colon with some microbubbles c…

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentPerforation (oil well)ColonoscopyPeritonitisBacteremiaClinical Practice03 medical and health sciences0302 clinical medicineEnteral NutritionmedicineHumansLaparoscopyColoring AgentsPerforationmedicine.diagnostic_testTattooingbusiness.industryTransverse colonEndoscopyColonoscopyMiddle Agedmedicine.diseaseEndoscopy; Perforation; Surgery; Tattoing; SurgeryPolypectomyCarbonSurgeryEndoscopyAnti-Bacterial AgentsTattoing030104 developmental biologyTreatment OutcomeIntestinal Perforation030220 oncology & carcinogenesisSurgeryFemaleLipomabusinessComplicationColorectal NeoplasmsTomography X-Ray Computed
researchProduct

Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Sy…

2021

Abstract Purpose To determine impact of risk-reducing hysterectomy and bilateral salpingo-oophorectomy (BSO) on gynecological cancer incidence and death in heterozygotes of pathogenic MMR ( path_MMR ) variants. Methods The Prospective Lynch Syndrome Database was used to investigate the effects of gynecological risk-reducing surgery (RRS) at different ages. Results Risk-reducing hysterectomy at 25 years of age prevents endometrial cancer before 50 years in 15%, 18%, 13%, and 0% of path_MLH1 , path_MSH2 , path_MSH6 , and path_PMS2 heterozygotes and death in 2%, 2%, 1%, and 0%, respectively. Risk-reducing BSO at 25 years of age prevents ovarian cancer before 50 years in 6%, 11%, 2%, and 0% and…

0301 basic medicinemedicine.medical_treatmentDNA Mismatch RepairGynecologic surgery0302 clinical medicineMalalties hereditàriesProspective StudiesProspective cohort studyGenetics (clinical)Mismatch Repair Endonuclease PMS2Incidence (epidemiology)Middle Aged16. Peace & justiceLynch syndrome3. Good health030220 oncology & carcinogenesisFemalesyöpätauditMutL Protein Homolog 1Genetic diseasesHeterozygotemedicine.medical_specialtySalpingo-oophorectomyCirurgia ginecològicaHysterectomyArticle03 medical and health sciencesCàncer colorectalCAPP2medicineHumansLynchin oireyhtymäGynecologyperinnölliset tauditHysterectomyHEREDITARY COLORECTAL-CANCERbusiness.industryEndometrial cancerCancermedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisColorectal cancerASPIRIN030104 developmental biologyClinical researchLynch syndrome3121 General medicine internal medicine and other clinical medicinekohdunpoisto3111 BiomedicineOvarian cancerbusiness
researchProduct

Lipoproteins LDL versus HDL as nanocarriers to target either cancer cells or macrophages

2020

free open access article 31 p.; International audience; In this work, we have explored natural unmodified low- and high-density lipoproteins (LDL and HDL) as selective delivery vectors in colorectal cancer therapy. We show in vitro in cultured cells and in vivo (NanoSPECT/CT) in the CT-26 mice colorectal cancer model that LDLs are mainly taken up by cancer cells, while HDLs are preferentially taken up by macrophages. We loaded LDLs with cisplatin and HDLs with the heat shock protein-70 inhibitor AC1LINNC, turning them into a pair of “Trojan horses” delivering drugs selectively to their target cells as demonstrated in vitro in human colorectal cancer cells and macrophages, and in vivo. Coupl…

0301 basic medicinemedicine.medical_treatmentcisplatinlcsh:Medicineheat shock protein inhibitorCancer immunotherapy[CHIM.THER]Chemical Sciences/Medicinal ChemistrySpectrum Analysis RamanMiceDrug Delivery Systems0302 clinical medicineCancer immunotherapyChemistryRselective cell targetingGeneral Medicine3. Good healthLipoproteins LDLOncology030220 oncology & carcinogenesisMedicinecancer therapylipids (amino acids peptides and proteins)Colorectal NeoplasmsLipoproteins HDLResearch Articlemedicine.drug[CHIM.THER] Chemical Sciences/Medicinal ChemistryLipoproteinsTherapeuticsCell Line03 medical and health sciencesImmune systemIn vivoCell Line TumormedicinevectorizationAnimalsHumansCisplatinMacrophageslcsh:RCancermedicine.diseaseColorectal cancerIn vitro030104 developmental biologyCancer cellCancer researchNanocarriers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.

2017

ObjectiveCancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies.DesignTo discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein mic…

0301 basic medicinep53DNA ReplicationCELL CYCLE CONTROLDNA damageColorectal cancerColonmedicine.medical_treatmentAntineoplastic AgentsBiologyBioinformaticsmedicine.disease_causeDNA DAMAGETargeted therapy03 medical and health sciencesCancer stem cellCell Line TumormedicineHumansCHEK11506DRUG DEVELOPMENTOligonucleotide Array Sequence AnalysisMutationCOLORECTAL CANCERSettore MED/06 - ONCOLOGIA MEDICAGastroenterologyCHEMOTHERAPYmedicine.diseaseImmunohistochemistryPrexasertib030104 developmental biologyPyrazinesCheckpoint Kinase 1MutationCancer researchNeoplastic Stem CellsPyrazolesStem cellTumor Suppressor Protein p53Colorectal NeoplasmsGut
researchProduct

WNT2 activation through proximal germline deletion predisposes to small intestinal neuroendocrine tumors and intestinal adenocarcinomas

2021

Abstract Many hereditary cancer syndromes are associated with an increased risk of small and large intestinal adenocarcinomas. However, conditions bearing a high risk to both adenocarcinomas and neuroendocrine tumors are yet to be described. We studied a family with 16 individuals in four generations affected by a wide spectrum of intestinal tumors, including hyperplastic polyps, adenomas, small intestinal neuroendocrine tumors, and colorectal and small intestinal adenocarcinomas. To assess the genetic susceptibility and understand the novel phenotype, we utilized multiple molecular methods, including whole genome sequencing, RNA sequencing, single cell sequencing, RNA in situ hybridization…

AdenomaAcademicSubjects/SCI01140DOMAINSadenokarsinoomaCANCER-RISKIn situ hybridizationsuolistosyövätAdenocarcinomaBiologyNeuroendocrine tumorsGermlineWnt2 Proteinperinnöllinen alttius03 medical and health sciences0302 clinical medicineWNT2GeneticsGenetic predispositionmedicineHumansIntestinal MucosaMUTATIONMolecular BiologyGenetics (clinical)030304 developmental biologypaksusuolisyöpäCARCINOID-TUMORS0303 health sciencesperinnölliset tauditCYSTIC-FIBROSISGeneral MedicineNATIONWIDEmedicine.diseaseIntestinal epithelium3. Good healthGENOMENeuroendocrine TumorsHyperplastic PolypSingle cell sequencing3121 General medicine internal medicine and other clinical medicine030220 oncology & carcinogenesisMAPCancer researchsyöpätaudit3111 BiomedicineGeneral Articlegeneettiset tekijätColorectal Neoplasms
researchProduct

Dietary fatty acids and recurrence of colorectal adenomas in a European intervention trial.

2008

Epidemiological studies have provided inconsistent data about the role of dietary fatty acids in colorectal cancer, and few studies have addressed their role in colorectal adenoma. The aim of the study was to assess the risk of overall adenoma recurrence associated with dietary consumption of total fat, subtypes of fat, and specific fatty acids (oleic acid, linoleic acid, alpha-linolenic acid). The study sample was composed of 523 patients with confirmed adenomas at the index colonoscopy, 35 to 75 yr old, who completed the European fiber-calcium intervention trial and had an initial dietary assessment using a qualitative and quantitative food questionnaire. The overall 3-yr recurrence rate …

AdenomaAdultMaleCancer Researchmedicine.medical_specialtyAdenomaColorectal cancerLinoleic acidMedicine (miscellaneous)Colorectal adenomaGastroenterologyLinoleic Acidchemistry.chemical_compoundRisk FactorsInternal medicineSurveys and QuestionnairesEpidemiologymedicineOdds RatioHumansAgedchemistry.chemical_classificationNutrition and Dieteticsbusiness.industryFatty AcidsOdds ratioMiddle Agedmedicine.diseaseDietary FatsDietEuropeOleic acidOncologychemistryFatty Acids UnsaturatedFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsPolyunsaturated fatty acidNutrition and cancer
researchProduct